Disease · HP_0001891

Iron deficiency anemia

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. Iron deficiency anemia. Diseases, record HP_0001891. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/HP_0001891

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: Iron deficiency anemia; Open Targets
Open Targets ID: HP_0001891; Open Targets
Other names: Ferropenic, Iron deficiency anaemia; Open Targets
Disease Ontology: DOID:11758; Disease Ontology
NCI Thesaurus: C84484; NCI Thesaurus
Highest stage of its drugs: Approval, for 31 of its 54 drugs, from DailyMed, EMA Human Drugs, FDA, PMDA and TTD; Open Targets

Drugs54

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
FERRIC CARBOXYMALTOSE	CHEMBL2108597		Approval	DailyMed, PMDA and TTD	93	89	50	Drugs and targets
FERROUS SULFATE	CHEMBL1200830	Small molecule	Approval	TTD	89	88	50	Drugs and targets
IRON ISOMALTOSIDE 1000	CHEMBL4298046		Approval	TTD	69	67	15	Drugs and targets
FERRIC OXYHYDROXIDE	CHEMBL4802224	Small molecule	Approval	TTD	46	45	2	Drugs and targets
IRON SUCROSE	CHEMBL1200823	Small molecule	Approval	DailyMed	32	28	28	Drugs and targets
FERUMOXYTOL	CHEMBL1201867		Approval	TTD	23	21	21	Drugs and targets
FERRIC DERISOMALTOSE	CHEMBL4298187	Oligosaccharide	Approval	FDA	22	20	11	Drugs and targets
FERROUS FUMARATE	CHEMBL1200640	Small molecule	Approval	DailyMed	20	14	14	Drugs and targets
IRON DEXTRAN	CHEMBL1201544		Approval	DailyMed and TTD	17	10	10	Drugs and targets
FERRIC MALTOL	CHEMBL4298110	Small molecule	Approval	EMA Human Drugs, FDA and TTD	11	7	7	Drugs and targets

1 to 10 of 54

See all 54 drugs

Targets10

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
EPOR	Erythropoietin receptor	3	Erythropoietin receptor agonist	Unknown	https://conductscience.org/library/genes/2057	Drugs and targets
VDR	Vitamin D3 receptor	2	Vitamin D receptor agonist	Approval	https://conductscience.org/library/genes/7421	Drugs and targets
ATP4A	Potassium-transporting ATPase	1	Potassium-transporting ATPase inhibitor	Unknown	https://conductscience.org/library/genes/495	Drugs and targets
ATP4B	Potassium-transporting ATPase	1	Potassium-transporting ATPase inhibitor	Unknown	https://conductscience.org/library/genes/496	Drugs and targets
CRBN	CRL4(CRBN) E3 ubiquitin ligase	1	CRL4(CRBN) E3 ubiquitin ligase inhibitor	Unknown	https://conductscience.org/library/genes/51185	Drugs and targets
CUL4A	CRL4(CRBN) E3 ubiquitin ligase	1	CRL4(CRBN) E3 ubiquitin ligase inhibitor	Unknown	https://conductscience.org/library/genes/8451	Drugs and targets
DDB1	CRL4(CRBN) E3 ubiquitin ligase	1	CRL4(CRBN) E3 ubiquitin ligase inhibitor	Unknown	https://conductscience.org/library/genes/1642	Drugs and targets
PGR	Progesterone receptor	1	Progesterone receptor agonist	Unknown	https://conductscience.org/library/genes/5241	Drugs and targets
RBX1	CRL4(CRBN) E3 ubiquitin ligase	1	CRL4(CRBN) E3 ubiquitin ligase inhibitor	Unknown	https://conductscience.org/library/genes/9978	Drugs and targets
SLC10A2	Ileal sodium/bile acid cotransporter	1	Ileal bile acid transporter inhibitor	Unknown	https://conductscience.org/library/genes/6555	Drugs and targets

Trials175

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 23 more are not shown, since the checks do not confirm them.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT00981045	Evaluation of Efficacy and Safety of Ferric Carboxymaltose (FCM) in Patients With Iron Deficiency Anemia and Impaired Renal Function	Phase 3	2,561	2013-10-18	Iron Deficiency Anemia, Impaired Renal Function	FERRIC CARBOXYMALTOSE	Its record names the disease	ClinicalTrials.gov
NCT00548860	Safety of FCM vs. Standard of Care in Treating Iron Deficiency Anemia in Heavy Uterine Bleeding and Post Partum Patients	Phase 3	2,018	2015-05-29	Anemia	FERRIC CARBOXYMALTOSE	Its record names the disease	ClinicalTrials.gov
NCT02694978	A Phase III Safety Study of Ferumoxytol Compared to Ferric Carboxymaltose for the Treatment of Iron Deficiency Anemia (IDA)	Phase 3	2,014	2018-06-11	Iron Deficiency Anemia	FERRIC CARBOXYMALTOSE, FERUMOXYTOL	Its record names the disease	ClinicalTrials.gov
NCT02940860	Iron Isomaltoside/Ferric Derisomaltose vs Iron Sucrose for Treatment of Iron Deficiency Anemia in Non-Dialysis-Dependent Chronic Kidney Disease	Phase 3	1,538	2020-03-06	Iron Deficiency Anaemia, Iron Deficiency Anemia, Chronic Kidney Disease	FERRIC DERISOMALTOSE, IRON ISOMALTOSIDE 1000, IRON SUCROSE	Its record names the disease	ClinicalTrials.gov
NCT02940886	Iron Isomaltoside/Ferric Derisomaltose vs Iron Sucrose for the Treatment of Iron Deficiency Anemia (IDA)	Phase 3	1,512	2020-03-10	Iron Deficiency Anaemia, Iron Deficiency Anemia	FERRIC DERISOMALTOSE, IRON ISOMALTOSIDE 1000, IRON SUCROSE	Its record names the disease	ClinicalTrials.gov
NCT01950247	Evaluate the Utility of Serum Hepcidin Levels to Predict Response to Oral or IV Iron	Phase 4	1,025	2025-05-22	Iron Deficiency Anemia (IDA)	FERRIC CARBOXYMALTOSE	Its record names the disease	ClinicalTrials.gov
NCT00982007	Efficacy and Safety of Intravenous Ferric Carboxymaltose (FCM) in Patients With Iron Deficiency Anemia (IDA)	Phase 3	997	2013-10-18	Iron Deficiency Anemia	FERRIC CARBOXYMALTOSE	Its record names the disease	ClinicalTrials.gov
NCT01114139	A Trial Comparing Ferumoxytol With Placebo for the Treatment of Iron Deficiency Anemia	Phase 3	812	2018-06-11	Iron Deficiency Anemia	FERUMOXYTOL	Its record names the disease	ClinicalTrials.gov
NCT00704353	Safety and Tolerability of a Single Dose of FCM vs. Standard of Care in Treating Iron Deficiency Anemia	Phase 3	735	2013-11-25	Anemia	FERRIC CARBOXYMALTOSE	Its record names the disease	ClinicalTrials.gov
NCT00703937	Safety and Tolerability of Ferric Carboxymaltose (FCM) Versus Standard of Care in Treating Iron Deficiency Anemia	Phase 3	708	2013-11-25	Anemia	FERRIC CARBOXYMALTOSE	Its record names the disease	ClinicalTrials.gov

1 to 10 of 175

See all 175 trials

Comparisons in its trials118

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Ferric Carboxymaltose (FCM) vs Iron Sucrose (Venofer): Proportion of Subjects Experiencing at Least One Event in the Primary Composite Safety Endpoint in the Randomized Population.	175 of 1,276	156 of 1,285	2,561	NCT00981045	Trial comparisons
Ferric Carboxymaltose (FCM) vs Iron Sucrose (Venofer): serious adverse events	202 of 1,276	197 of 1,285	2,561	NCT00981045	Trial comparisons
Ferric Carboxymaltose (FCM) vs Standard Medical Care (SMC): Evaluate the Safety of the Maximum Administered Dose, 15 mg/kg (up to a Maximum 1,000 mg) of FCM Compared to SMC.	6 of 996	22 of 1,022	2,018	NCT00548860	Trial comparisons
Ferric Carboxymaltose (FCM) vs Standard Medical Care (SMC): serious adverse events	6 of 996	22 of 1,022	2,018	NCT00548860	Trial comparisons
Ferumoxytol vs Ferric Carboxymaltose (FCM): serious adverse events	36 of 997	35 of 1,000	1,997	NCT02694978	Trial comparisons
Iron Isomaltoside/Ferric Derisomaltose vs Iron Sucrose: Hb Concentration of >12 g/dL at Any Time From Week 1 to Week 8	259 of 1,027	121 of 510	1,537	NCT02940860	Trial comparisons
Iron Isomaltoside/Ferric Derisomaltose vs Iron Sucrose: Hb Concentration Increase of ≥2 g/dL at Any Time From Week 1 to Week 8	307 of 1,027	133 of 510	1,537	NCT02940860	Trial comparisons
Iron Isomaltoside/Ferric Derisomaltose vs Iron Sucrose: Incidence of Protocol-defined Serious or Severe Hypersensitivity Reactions	3 of 1,019	0 of 506	1,525	NCT02940860	Trial comparisons
Iron Isomaltoside/Ferric Derisomaltose vs Iron Sucrose: Composite Cardiovascular Adverse Events (AEs)	42 of 1,019	35 of 506	1,525	NCT02940860	Trial comparisons
Iron Isomaltoside/Ferric Derisomaltose vs Iron Sucrose: deaths from any cause	3 of 1,019	3 of 506	1,525	NCT02940860	Trial comparisons

1 to 10 of 118

See all 118 comparisons in its trials

Papers from its trials85

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
41860281	RESULT	1	PubMed
36107229	RESULT	2	PubMed
35113024	RESULT	1	PubMed
35011099	RESULT	1	PubMed
34839481	RESULT	2	PubMed
33946398	RESULT	1	PubMed
32053933	RESULT	1	PubMed
31811820	RESULT	1	PubMed
31413088	RESULT	1	PubMed
31243803	RESULT	2	PubMed

1 to 10 of 85

See all 85 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/HP_0001891

GET https://conductscience.org/api/diseases/v1/HP_0001891/drugs?page=2

API reference For AI assistants